Overview
- Mid-September analyst moves pushed optimism higher with Citigroup setting a Street-high $1,600 target and Berenberg lifting its target to $1,400, while the stock has fallen roughly 8% over the past month.
- Eli Lilly is the clear market leader in GLP-1 obesity and diabetes drugs, reporting about $14.9 billion in combined quarterly sales and roughly 60% global market share for its incretin portfolio.
- Pipeline milestones are the key upside drivers: retatrutide produced 'bariatric-surgery-level' weight loss in trials and Lilly plans a BLA filing in Q1 2027, and oral GLP-1 Foundayo has early commercial traction with roughly $100 million in Q2 sales and a possible imminent diabetes approval.
- The company recorded approximately $2.78 billion of acquired IPR&D charges from recent deals, a non-cash accounting hit that lowered GAAP earnings and prompted investor questions about capital allocation.
- Analyst sentiment remains strongly bullish overall, with a consensus Strong Buy and an average price target near $1,376, but near-term valuation now hinges on regulatory outcomes for retatrutide and Foundayo plus pricing and mix dynamics in the GLP-1 market.